SGLT2 Inhibitors Superior to Other Oral Diabetes Drugs for People with Type 2 Diabetes and NAFLD
February 12th 2024A large retrospective study of patients in South Korea shows that the SGLT2 inhibitors seem to do a better job with bringing about regression of nonalcoholic fatty liver disease.
Read More
FDA Updates for the Week of Feb. 5, 2024: Review Dates and Advisory Committee Meetings Scheduled
February 10th 2024The FDA has set PDUFA dates for several products: Arexvy to prevent RSV in 50 to the 59 population, for acoramidis in heart failure indication, and for an engineered tissue for vascular replacement. The agency has also scheduled an advisory committee meeting for Abecma in supplemental multiple myeloma indication. Additionally, Amneal has resubmitted its application for novel Parkinson’s therapy.
Read More
Community Health Centers Pose as Major Stepping Stone in Post-Incarceration Healthcare
February 10th 2024Providing support to those transitioning into life after incarceration is crucial. This group often faces complex health risks after their release, and maintaining consistent access to substance use disorder treatment plays a significant role in reducing the risk of reincarceration, relapse, and overdose.
Read More
In a retrospective study, researchers from Humana in Louisville, KY, compared clinical outcomes, time on treatment, healthcare resources utilization, and relative costs in patients with MS that were newly initiated on one of the following oral DMTs: dimethyl fumarate, fingolimod, or teriflunomide.
Read More
Studies have shown that the use of oral corticosteroids in patients with UC is associated with higher rates of adverse effects and use of healthcare resources compared with biologics or immunosuppressants. However, there is little research focusing on the economic and clinical burden of chronic corticosteroid use among people living with UC.
Read More
Republicans voted in favor of a bill that would prohibit the use quality-adjusted life years (QALY) metrics by federal agencies, Medicare Advantage plans and Medicaid managed care organizations. Some patient groups celebrated the passage. Experts have worried that "similar measures" language could stifle all comparative effectiveness analysis.
Read More